Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Updates from JULIET: correlative analyses and clinical characteristics associated with efficacy

Edmund Waller • 23 Aug 2020
EBMT 2020
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma CAR-T Tisagenlecleucel
JULIET

Edmund Waller, MD, PhD, FACP, of the Division of Hematology/Oncology, Emory Clinic, Atlanta, GA, updates us on the correlative analyses of patients and clinical characteristics associated with efficacy in the JULIET trial (NCT02445248), a Phase II evaluating tisagenlecleucel in adult relapsed/refractory diffuse large B-cell lymphoma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Edmund Waller

1:12
Managing GvHD in patients undergoing SCT
Edmund Waller • 8 Sep 2023
1:46
Optimizing conditioning regimens in patients with AML undergoing alloSCT
Edmund Waller • 8 Sep 2023
2:09
Improving transplantation outcomes in patients with active AML: current approaches & future outlooks
Edmund Waller • 8 Sep 2023
4:18
Duvelisib in CAR T-cell therapy for CLL
Edmund Waller • 1 Sep 2020

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals